Treace Medical Concepts, Inc.

NASDAQ:TMCI

Medical - Devices

Healthcare
$4.53 +1.87%

+$0.08 today

Market cap
$296.98M
Beta
1.41
P/E (TTM)
-4.3
EPS (TTM)
-$0.95
52W Low $1.17High $7.78

Volume 0.18M

Average 0.73M

TMCI Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

Treace Medical Concepts, Inc.NASDAQ: TMCI

Revenue · Q1 FY2026 · quarter ended Mar 2026

Revenue declines year over year

Q1 FY2026 revenue of $47.2M fell 10.2% year over year, behind the -1.7% change in trailing-twelve-month revenue. Sequentially, it fell 24.5% from the prior quarter. Over 3 fiscal years it compounded at +14.5% a year.

Context

  • Revenue increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether revenue reaches the consensus estimate from 4 analysts of $207.94M (-2.2%) for the fiscal year ending Dec 2026, a slowdown from the +1.6% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$47.2M-24.5% QoQ
Last fiscal yearDec 2025
$212.69M+1.6% YoY
LTMMar 2026
$207.32M-1.7% YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-10.2%-7.1%+3.1 pp
1 year+1.6%-2.2%-3.8 pp
3-year CAGR+14.5%+3.3%-11.1 pp
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Revenue history

USD · from the income statement

Latest · FY2025
212.69M USD
Year-over-year change
+1.6%
4-year CAGR
+22.5%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How TMCI compares with its peers on the latest reported figures

  • TMCI's LTM Mar 2026 revenue of $207.32M is the 5th highest of the 8 companies compared; the peer median is $243.3M.
  • Its year-over-year change of -1.7% is the 6th highest of 8, against a peer median of +9.6%.
  • Over three fiscal years its annual growth of +14.5% compares with a peer median of +25.8%.
TMCI Competitors Peer median
Revenue for TMCI and competitors
Company Period LTM YoY 3-year CAGR
BVSBioventus Inc.LTM Mar 2026$576.3M +1.5%+3.5%
TOIThe Oncology Institute, Inc.LTM Mar 2026$545.76M +35.4%+25.8%
EOLSEvolus, Inc.LTM Mar 2026$301.79M +9.6%+26.0%
KIDSOrthoPediatrics Corp.LTM Mar 2026$243.3M +14.5%+24.6%
TMCITreace Medical Concepts, Inc.LTM Mar 2026$207.32M -1.7%+14.5%
RXSTRxSight, Inc.LTM Mar 2026$127.48M -19.5%+40.0%
CBLLCeriBell, Inc.LTM Mar 2026$95.07M +33.7%+50.9%
LABStandard BioTools Inc.LTM Mar 2026$86.26M -35.8%-4.5%
Peer median (excluding TMCI) $243.3M+9.6%+25.8%

Competitors are the stored peer set for TMCI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue94.42M141.84M187.12M209.36M212.69M
Cost of Revenue16.89M27.52M35.18M41.09M42.94M
Gross Profit77.53M114.32M151.94M168.26M169.75M
Gross Margin82.1%80.6%81.2%80.4%79.8%
Research & Development10.2M13.58M15.44M20.59M20.28M
Selling, General & Admin83.84M137.57M187.93M203.36M203.62M
Operating Expenses94.04M149.16M203.37M223.95M223.91M
Depreciation & Amortization685K2.13M5.35M8.42M10.5M
EBITDA(15.81M)(36.28M)(39.01M)(42.07M)(43.18M)
EBITDA Margin-16.7%-25.6%-20.8%-20.1%-20.3%
Operating Income(16.51M)(34.84M)(51.43M)(55.69M)(54.15M)
Operating Margin-17.5%-24.6%-27.5%-26.6%-25.5%
Interest Income18K1.31M6.73M4.88M2.78M
Interest Expense4.06M4.4M5.17M5.26M5.32M
Other Income / Expenses(4.04M)(7.97M)1.9M(55K)(4.85M)
Income Before Tax(20.55M)(42.82M)(49.53M)(55.74M)(59M)
Pre-Tax Margin-21.8%-30.2%-26.5%-26.6%-27.7%
Income Tax Expense00000
Net Income(20.55M)(42.82M)(49.53M)(55.74M)(59M)
Net Margin-21.8%-30.2%-26.5%-26.6%-27.7%
EPS (Basic)(0.38)(0.77)(0.81)(0.90)(0.93)
EPS (Diluted)(0.38)(0.77)(0.81)(0.90)(0.93)
Weighted Avg Shares54.18M55.28M60.85M62.11M63.27M
Weighted Avg Shares (Diluted)54.18M55.28M60.85M62.11M63.27M

Treace Medical Concepts, Inc.

NASDAQ:TMCI

Intrinsic Alpha fair value

Locked

Current Price

$4.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.